Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers.
Adult
Aged
Aged, 80 and over
Area Under Curve
Carcinoma, Non-Small-Cell Lung
/ diagnosis
ErbB Receptors
/ genetics
Female
Humans
Image Processing, Computer-Assisted
/ methods
Japan
Lung Neoplasms
/ diagnosis
Malaysia
Male
Middle Aged
Mutation
ROC Curve
Support Vector Machine
Tomography, X-Ray Computed
United States
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
09
2020
accepted:
09
12
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
24
4
2021
Statut:
epublish
Résumé
To propose a novel robust radiogenomics approach to the identification of epidermal growth factor receptor (EGFR) mutations among patients with non-small cell lung cancer (NSCLC) using Betti numbers (BNs). Contrast enhanced computed tomography (CT) images of 194 multi-racial NSCLC patients (79 EGFR mutants and 115 wildtypes) were collected from three different countries using 5 manufacturers' scanners with a variety of scanning parameters. Ninety-nine cases obtained from the University of Malaya Medical Centre (UMMC) in Malaysia were used for training and validation procedures. Forty-one cases collected from the Kyushu University Hospital (KUH) in Japan and fifty-four cases obtained from The Cancer Imaging Archive (TCIA) in America were used for a test procedure. Radiomic features were obtained from BN maps, which represent topologically invariant heterogeneous characteristics of lung cancer on CT images, by applying histogram- and texture-based feature computations. A BN-based signature was determined using support vector machine (SVM) models with the best combination of features that maximized a robustness index (RI) which defined a higher total area under receiver operating characteristics curves (AUCs) and lower difference of AUCs between the training and the validation. The SVM model was built using the signature and optimized in a five-fold cross validation. The BN-based model was compared to conventional original image (OI)- and wavelet-decomposition (WD)-based models with respect to the RI between the validation and the test. The BN-based model showed a higher RI of 1.51 compared with the models based on the OI (RI: 1.33) and the WD (RI: 1.29). The proposed model showed higher robustness than the conventional models in the identification of EGFR mutations among NSCLC patients. The results suggested the robustness of the BN-based approach against variations in image scanner/scanning parameters.
Identifiants
pubmed: 33428651
doi: 10.1371/journal.pone.0244354
pii: PONE-D-20-30432
pmc: PMC7799813
doi:
Substances chimiques
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244354Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Diagn Pathol. 2015 Apr 24;10:36
pubmed: 25907563
Eur Respir J. 2019 Mar 28;53(3):
pubmed: 30635290
PLoS One. 2019 Jan 22;14(1):e0210720
pubmed: 30668605
Med Phys. 2018 Nov;45(11):5116-5128
pubmed: 30230556
Lancet Oncol. 2009 May;10(5):432-3
pubmed: 19410185
Thorax. 2003 Nov;58(11):920-36
pubmed: 14586042
Sci Rep. 2019 Jun 19;9(1):8764
pubmed: 31217445
Comput Med Imaging Graph. 2016 Mar;48:1-8
pubmed: 26745258
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Oncologist. 2019 Nov;24(11):e1156-e1164
pubmed: 30936378
Med Phys. 2020 Jun;47(5):2197-2205
pubmed: 32096876
Transl Lung Cancer Res. 2015 Apr;4(2):156-64
pubmed: 25870798
Lung Cancer. 2019 Jun;132:28-35
pubmed: 31097090
Transl Oncol. 2017 Dec;10(6):886-894
pubmed: 28930698
Lung Cancer. 2017 Nov;113:37-44
pubmed: 29110846
PLoS One. 2015 May 04;10(5):e0124165
pubmed: 25938522
Radiology. 2016 Jul;280(1):271-80
pubmed: 26937803
Cell Mol Life Sci. 2008 May;65(10):1566-84
pubmed: 18259690
Phys Med. 2020 Jan;69:90-100
pubmed: 31855844
Sci Data. 2018 Oct 16;5:180202
pubmed: 30325352
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Ann Oncol. 2014 Sep;25(9):1681-1690
pubmed: 24718890
AJR Am J Roentgenol. 2011 Jun;196(6):W678-82
pubmed: 21606253
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Sci Rep. 2019 Feb 4;9(1):1139
pubmed: 30718811
Sci Rep. 2018 Dec 17;8(1):17913
pubmed: 30559455
PLoS One. 2012;7(8):e43842
pubmed: 22952784
Int J Crit Illn Inj Sci. 2015 Jul-Sep;5(3):189-95
pubmed: 26557489
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Tomography. 2016 Dec;2(4):430-437
pubmed: 28149958
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
J Thorac Dis. 2014 Sep;6(9):1230-8
pubmed: 25276365
Invest Radiol. 2015 Nov;50(11):757-65
pubmed: 26115366
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
IEEE J Biomed Health Inform. 2020 Jun 16;PP:
pubmed: 32750940
J Digit Imaging. 2016 Aug;29(4):476-87
pubmed: 26847203
J Radiat Res. 2019 Jan 1;60(1):150-157
pubmed: 30247662
Lung Cancer. 2015 Mar;87(3):272-7
pubmed: 25582278